Ignite Creation Date:
2024-05-06 @ 3:56 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04801966
Status:
TERMINATED
Last Update Posted:
2023-05-10
First Post:
2021-03-13
Brief Title:
Safety and Oversight of the Individually Tailored Treatment Approach A Novel Pilot Study
Sponsor:
Peter MacCallum Cancer Centre Australia
Organization:
Peter MacCallum Cancer Centre Australia
Study Overview
Official Title:
Safety and Oversight of the Individually Tailored Treatment Approach A Novel Pilot Study
Status:
TERMINATED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
low recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TAILOR
Brief Summary:
This study is looking at outcomes in people with advanced cancers who have exhausted standard treatment options and are accessing off indication or unregistered drugs or combinations of drugs through compassionate access from the manufacturer
Detailed Description:
Some advanced cancers have numerous standard treatment options that have proven efficacy in clinical trials However in other cancers there may be few or no standard treatment options with proven efficacy as determined in a large clinical trial This may be particularly the case for rare cancers in which there is a lack of clinical research When seriously ill patients run out of standard treatment options they will often consider non-standard treatment options such as treatments that are currently unapproved by the regulatory agency for the given indication The majority of clinicians and researchers agree that this is best received in a clinical trial setting as this provides ethical and clinical oversight as well as addresses prospectively defined research questions which can be publicly reported This allows the conclusions of the research to be available to the entire clinical and research community
In general an access program enables patient access to a non-reimbursed therapeutic agent outside of a clinical trial setting Compassionate access is typically for therapeutics that are not yet approved or TGA registered and are still considered investigational In general there is a negotiation between the pharmaceutical company and the clinician and patient regarding access to the therapeutic agent as well as whether the medicine will be provided free of charge or on some form of cost-sharing arrangement In Australia access to TGA non-registered medicines also requires an application via the Special Access Scheme For most cancer patients the use falls under category A for a patient defined as seriously ill This sub-study generally pertains to compassionate access to therapeutic agents Given the ad hoc nature of compassionate access for patients there is relatively little reported data on clinical outcomes
Compassionate access is an established process with increasing demands This study is designed to provide a framework for which patients treated with compassionate access therapeutics can register so that some of the limitations of ad hoc compassionate access programs can be overcome
A study committee will prospectively assess each individual patients detailed treatment approach in an objective and time-efficient manner If approved the patient may be eligible to register into the treatment phase of the study The study committee is essential to provide a balanced approach to understanding the rationale for the study treatment as well as potential safety issues that may arise As previously reported this is an essential component to improving patient oversight as well as equity
In general an access program enables patient access to a non-reimbursed therapeutic agent outside of a clinical trial setting Compassionate access is typically for therapeutics that are not yet approved or TGA registered and are still considered investigational In general there is a negotiation between the pharmaceutical company and the clinician and patient regarding access to the therapeutic agent as well as whether the medicine will be provided free of charge or on some form of cost-sharing arrangement In Australia access to TGA non-registered medicines also requires an application via the Special Access Scheme For most cancer patients the use falls under category A for a patient defined as seriously ill This sub-study generally pertains to compassionate access to therapeutic agents Given the ad hoc nature of compassionate access for patients there is relatively little reported data on clinical outcomes
Compassionate access is an established process with increasing demands This study is designed to provide a framework for which patients treated with compassionate access therapeutics can register so that some of the limitations of ad hoc compassionate access programs can be overcome
A study committee will prospectively assess each individual patients detailed treatment approach in an objective and time-efficient manner If approved the patient may be eligible to register into the treatment phase of the study The study committee is essential to provide a balanced approach to understanding the rationale for the study treatment as well as potential safety issues that may arise As previously reported this is an essential component to improving patient oversight as well as equity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None